- Halman et al. 2024 systematic review: 47 case reports of lithium + classical psychedelic. ~47% involved seizures, ~17% involved tonic-clonic events, ~30% involved prolonged psychotic reactions.
- This is the single highest-risk documented psychedelic-medication combination.
- Every Phase 2 and Phase 3 psilocybin trial protocol excludes lithium.
- Mechanism is not fully understood. Lithium’s effects on serotonergic and glutamatergic systems plus its narrow therapeutic window appear to combine badly with 5-HT2A activation.
- If you take lithium, do not microdose, macrodose, or experiment with classical psychedelics. The risk is not theoretical.
Why people ask this question
Lithium is prescribed for bipolar disorder, treatment-resistant depression, and as a cluster headache preventive. Patients on lithium are exactly the population most likely to be drawn to psilocybin: severe mood disorders, treatment-resistant presentations, the cluster-busters community.
This page exists because the answer is unambiguous and the cost of getting it wrong can be a seizure, hospitalization, or worse.
What the case-report data actually shows
Halman et al. (2024) J Psychopharmacol systematically reviewed psychedelic-medication interactions across the published literature and online forum reports. The lithium signal was the strongest:
| Outcome | Approximate frequency in 47 cases |
|---|---|
| Seizure (any type) | ~47% |
| Tonic-clonic seizure | ~17% |
| Status epilepticus | ~6% |
| Prolonged psychotic reaction | ~30% |
| Hospital admission | ~40% |
| Uneventful experience | Minority |
For comparison, the same review found case reports of SSRI + psychedelic combinations rarely involved seizure or psychosis at this frequency. Lithium is in a category of its own.
Mechanism (still uncertain)
The interaction is not fully characterized. Several non-exclusive hypotheses:
- Lowered seizure threshold. Lithium narrows the therapeutic window for many neurological events. 5-HT2A activation can independently affect cortical excitability. The combination appears to push some patients past threshold.
- Glutamatergic interaction. Lithium affects glutamate signaling. Psychedelics produce a glutamate surge through 5-HT2A on cortical pyramidal cells. The two together may overshoot.
- Lithium toxicity at threshold. Lithium has a narrow therapeutic-to-toxic ratio. Acute changes in hydration or kidney function during the dose can shift levels.
- Bipolar substrate. Patients on lithium are usually bipolar. Bipolar I is independently a contraindication for psychedelics. The lithium-psilocybin signal may overlap with the bipolar-psilocybin signal.
The mechanism uncertainty does not reduce the clinical certainty: across 47 cases, the outcome distribution is bad enough to make the combination a hard no.
Safer alternatives
If you are on lithium and considering psilocybin therapy, the workable paths:
Stay on lithium, skip psychedelics
Most often the right answer. Lithium has decades of evidence for bipolar and TRD. The downside of an “uneventful psilocybin session you did not have” is far smaller than the downside of a seizure.
Switch off lithium with psychiatrist
Possible for some bipolar II or TRD patients. Months-long supervised process. Switching to lamotrigine or other mood stabilizer is not always safe; mood-stabilizing alternatives have their own contraindications with psychedelics.
Ketamine instead
NMDA antagonist, different mechanism, compatible with most lithium regimens. FDA-approved for TRD as esketamine. Talk to your prescriber.
Cluster headache: BOL-148 if you can find it
For cluster patients on lithium, the non-hallucinogenic 2-bromo-LSD has shown anti-cluster activity (Karst 2010). Not yet approved or commercially available. Some research access.
Switching off lithium (with your psychiatrist)
This is a real medication change with real risks of mood relapse. Not a casual undertaking. The general process under psychiatric supervision:
- Month 1: Discuss with prescriber. Establish a switch plan if appropriate. Consider replacement mood stabilizer.
- Month 2-3: Slow lithium taper, typically 25% per 2-4 weeks, with mood monitoring.
- Month 4: Lithium-free. Confirm via serum level (should be undetectable). Mood stable on alternative.
- Month 5-6: Some clinicians wait 6 to 12 weeks lithium-free before any psilocybin protocol. Half-life and tissue redistribution mean serum-undetectable does not mean fully washed out from clinical perspective.
- Post-session: Resume mood stabilizer or stay off, decision with prescriber based on response and stability.
If someone has dosed psychedelics on lithium and develops:
Any seizure activity (any type) · Loss of consciousness · Severe confusion lasting hours · Inability to recognize people or surroundings · Combative or psychotic behavior beyond normal trip range · Lithium-toxicity signs (severe tremor, vomiting, ataxia, slurred speech).
Call 911 or your local emergency line immediately. Inform paramedics: “lithium plus psychedelic, possible seizure or lithium toxicity.” Bring lithium prescription bottle.
